Adverse events with disease modifying antirheumatic drugs (DMARD): A cohort study of leflunomide compared with other DMARD

Journal of Rheumatology

Volumn 31, Issue 10, 2004, Pages 1906-1911

  Cannon, Grant W ^a,d   Holden, William L ^b   Juhaeri, Juhaeri ^b   Dai, Wanju ^b   Scarazzini, Linda ^b   Stang, Paul ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

^c Galt Associates Inc   (United States)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Adverse effects; Antirheumatlc agents; Cohort studies; Methotrexate

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGIC PNEUMONITIS; APLASTIC ANEMIA; ARTICLE; BILIARY CIRRHOSIS; BLOOD TOXICITY; BRONCHITIS; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DRUG EXPOSURE; FEMALE; HEPATIC COMA; HEPATITIS; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; INFLUENZA; INSURANCE; JAUNDICE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER NECROSIS; LIVER TOXICITY; LOEFFLER PNEUMONIA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PANCREATITIS; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 5044250762     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Myers R, Hyslop T, Gerrity M, et al. Physician intention to recommend complete diagnostic evaluation in colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 1999;8:587-93.
2. Leone F, Grana J, McDermott P, MacPherson S, Hanchak N, Fish J. Pharmaceutically-based severity stratification of an asthmatic population. Resp Med 1999;93:788-93.
3. European Agency for the Evaluation of Medicinal Products. Public statement on leflunomide. London, March 2001. [Cited May 25, 2004]. Available from: http://www.emea.eu.int/pdfs/human/press/pus/561101en.pdf
4. FDA with PhRMA and AASLD. Drug-Induced Hepatotoxicity White Paper: Postmarketing considerations. November 2000. [Cited 2002, Dec 11]. Available from: http//www.fda.gov/cder/livertox/postmarket.pdf
5. Breslow N. Cohort analysis in epidemiology. In: Atkinson A, Feinberg S, editors. A celebration of statistics. New York: Springer-Verlag; 1985.
6. Breslow N, Day N. Statistical methods in cancer research. Vol II. The design and analysis of cohort studies. Lyon: International Agency for Research on Cancer; 1987;82:1-406.
7. Frome E. The analysis of rates using Poisson regression models. Biometrics 1983;39:665-74.
8. Holford T. The analysis of rates and survivorship using log-linear models. Biometrics 1980;36:299-305.
9. Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83.
10. McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993;20:1850-6.
11. Williams HJ, WilLkens RF, Samuelson CO Jr, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985;28:721-30.
12. McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993;20:1850-6.
13. Alarcon GS, Tracy IC, Blackburn WD. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989;32:671-6.
14. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.
15. Kremer JM, Furst DE, Weinblatt ME, Blotner SD. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996;23:459-61.
16. Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. Q J Med 2001;94:309-19.
17. Galindo-Rodriguez G, Avina-Zubieta JA, Russell AS, Suarez-Almazor ME. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study. J Rheumatol 1999;26:2337-43.
18. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
19. Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol 1996;23Suppl 44:13-22.
20. Pincus T, Callahan L. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993;19:123-51.
21. Movitt E, Davis A. Liver biopsy in rheumatoid arthritis. Am J Med 1953;226:516-20.
22. Lefkovits A, Farrow I. The liver in rheumatoid arthritis. Ann Rheum Dis 1955;14:162-9.
23. Ruderman E, Crawford J, Maier A, Liu J, Gravallese E, Weinblatt M. Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. Br J Rheumatol 1997;36:210-3.
24. Mills P, MacSween R, Dick W, More I, Watkinson G. Liver disease in rheumatoid arthritis. Scott Med J 1980;25:18-22.
25. Mills P, Sturrock R. Clinical associations between arthritis and liver disease. Ann Rheum Dis 1982;41:295-307.
26. Armstrong EP, Manuchehri F. Ambulatory care databases for managed care organizations. Am J Health Syst Pharm 1997;54:1973-83.
27. Deyo RA, Taylor VM, Diehr P, et al. Analysis of automated administrative and survey databases to study patterns and outcomes of care. Spine 1994;19 Suppl 18:2083S-91S.
28. Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther 1997;19:346-66.
29. Shatin D, Drinkard C, Stergachis A. United Health Group. In: Strom B, editor. Pharmacoepidemiology. 3rd ed. Chichester: John Wiley & Sons; 2000:295-306.